<SEC-DOCUMENT>0001193125-14-230421.txt : 20140624
<SEC-HEADER>0001193125-14-230421.hdr.sgml : 20140624
<ACCEPTANCE-DATETIME>20140609163052
ACCESSION NUMBER:		0001193125-14-230421
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140605
ITEM INFORMATION:		Submission of Matters to a Vote of Security Holders
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140609
DATE AS OF CHANGE:		20140609

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		14899470

	BUSINESS ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d739104d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K </B></P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>Date of Report (Date of Earliest Event Reported):<B> June&nbsp;9, 2014 (June 5, 2014) </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman" ALIGN="center"><B>ARCA biopharma, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exact Name of Registrant as Specified in Charter) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><B>000-22873</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><B>36-3855489</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(State or Other Jurisdiction</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">of Incorporation)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center">(Commission File Number)</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(I.R.S. Employer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Identification No.)</P></TD></TR></TABLE>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>11080 CirclePoint Road, Suite 140, Westminster, CO 80020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Address of Principal Executive Offices) (Zip Code) </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(720) 940-2200 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Registrant&#146;s Telephone Number, Including Area Code) </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Former
Name or Former Address, if Changed Since Last Report) </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;5.07 Submission of Matters to a Vote of Security Holders </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;5, 2014, the Company held it&#146;s 2014 Annual Meeting of Stockholders (the &#147;2014 Annual Meeting&#148;) at which the Company&#146;s
stockholders voted upon (i)&nbsp;the election of Company nominees Dr.&nbsp;Michael&nbsp;R. Bristow and Mr.&nbsp;Robert&nbsp;E. Conway, to the Company&#146;s Board of Directors (the &#147;Board&#148;) for a three-year term ending at the 2017 Annual
Meeting of Stockholders and (ii)&nbsp;the ratification of the selection of KPMG LLP as the Company&#146;s independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The stockholders elected both director nominees and ratified the selection of KPMG LLP as the Company&#146;s independent registered public accounting firm for
the fiscal year ending December&nbsp;31, 2014.&nbsp;The tabulation of votes cast with respect to each matter voted upon, as applicable, was as follows: </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1. Election of Directors </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="29%"></TD>
<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:29.30pt; font-size:8pt; font-family:Times New Roman">Nominee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:11.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">For</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:29.70pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Withheld</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:59.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><FONT STYLE="white-space:nowrap">Broker&nbsp;Non-Votes</FONT></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael R. Bristow, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3,698,688</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">119,242</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">10,028,926</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert E. Conway</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3,707,261</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">110,669</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">10,028,926</TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">2. Ratification of the selection of KPMG LLP as the Company&#146;s independent registered public accounting
firm for the fiscal year ending December&nbsp;31, 2014 </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="30%"></TD>
<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:11.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">For</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:24.85pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Against</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:38.15pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Abstentions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:59.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Broker Non-Votes</P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">13,763,868</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">72,354</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">10,634</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:28pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;8.01 Other Events </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Appointment of Robert E. Conway as Chairman of the Board of Directors </I></B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;5, 2014, the Board also appointed Mr.&nbsp;Conway as the Chairman of the Board of the Company. A copy of the press release relating to Mr.
Conway&#146;s election is attached hereto as Exhibit 99.1 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section 9 &#151; Financial Statements and Exhibits</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item 9.01. Financial Statements and Exhibits. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Exhibits. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD WIDTH="88%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:55.75pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit&nbsp;Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">99.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Press Release titled &#147;Robert E. Conway Elected Chairman of ARCA biopharma Board of Directors&#148; dated June 9, 2014.</P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SIGNATURES </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:26pt; margin-bottom:0pt; text-indent:6%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: June&nbsp;9, 2014 </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="3" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARCA biopharma, Inc.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Registrant)</P></TD></TR>


<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Christopher D. Ozeroff</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Christopher D. Ozeroff</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Senior Vice President and General Counsel</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEX TO EXHIBITS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit&nbsp;Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">99.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Press Release titled &#147;Robert E. Conway Elected Chairman of ARCA biopharma Board of Directors&#148; dated June 9, 2014.</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d739104dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P>&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g739104arca.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>ROBERT E. CONWAY ELECTED CHAIRMAN OF ARCA BIOPHARMA </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>BOARD OF DIRECTORS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Westminster, CO,
June&nbsp;9, 2014</I> &#150; ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that Robert E. Conway, has been elected Chairman of the
Company&#146;s Board of Directors. He serves on the Audit and Compensation Committees of the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Conway has over 30 years of
executive leadership experience in the pharmaceutical and biotechnology industries. Mr.&nbsp;Conway served as the Chief Executive Officer and member of the Board of Directors of Array BioPharma from 1999 to 2012. Array is a biopharmaceutical company
focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and inflammatory diseases. Prior to joining Array, Mr.&nbsp;Conway was the Chief Operating Officer and Executive
Vice President of Hill Top Research, Inc., a clinical research services company, from 1996 to 1999. He also held various executive positions for Corning Inc. including Corporate Vice President and General Manager of Corning Hazleton, Inc., a
contract research organization. Mr.&nbsp;Conway serves as the Chairman of Wall Family Enterprise, a leading library and education supplies company. He is on the Board of Directors of eResearch Technology, Inc. In addition, Mr.&nbsp;Conway is a
member of the Strategic Advisory Committee of Genstar Capital, LLC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Bob&#146;s experience and leadership are a tremendous asset to ARCA,&#148; said
Dr.&nbsp;Michael&nbsp;R. Bristow, President and Chief Executive Officer of ARCA. &#147;With his significant experience in leading both drug development efforts and companies in the biopharmaceutical sector, Bob&#146;s input and guidance will be
valuable to the ARCA Board as we continue the development of Gencaro and look to deliver value to our stockholders.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I am honored to accept
this role with the ARCA Board of Directors,&#148; said Mr.&nbsp;Conway. &#147;This is an exciting time for the organization with the GENETIC-AF trial under way. We believe there is an unmet medical need for new atrial fibrillation treatments. The
GENETIC-AF trial, conducted with the collaboration of Medtronic, will hopefully provide important new data for the atrial fibrillation community.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About ARCA biopharma </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ARCA biopharma is dedicated to
developing genetically-targeted therapies for cardiovascular diseases. The Company&#146;s lead product candidate, Gencaro<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> (bucindolol hydrochloride), is an investigational, pharmacologically
unique beta-blocker and mild vasodilator being developed for atrial fibrillation. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first
genetically-targeted atrial fibrillation prevention treatment. ARCA has a collaboration with Medtronic, Inc. for support of the GENETIC-AF trial. For more information please visit <U>www.arcabiopharma.com</U>. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safe Harbor Statement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains &#147;forward-looking statements&#148; for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of
1995. These statements include, but are not limited to, statements regarding, potential timing for patient enrollment in the GENETIC-AF trial, the sufficiency of the Company&#146;s capital to support its operations, the potential for genetic
variations to predict individual patient response to Gencaro, Gencaro&#146;s potential to treat atrial fibrillation, future treatment options for patients with atrial fibrillation, and the potential for Gencaro to be the first genetically-targeted
atrial fibrillation prevention treatment. Such statements are based on management&#146;s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking
statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: the Company&#146;s financial resources and whether they will be sufficient to meet the Company&#146;s business objectives and
operational requirements; results of earlier clinical trials may not be confirmed in future trials, the protection and market exclusivity provided by the Company&#146;s intellectual property; risks related to the drug discovery and the regulatory
approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA&#146;s filings with the SEC, including without limitation the Company&#146;s annual
report on Form 10-K for the year ended December&nbsp;31, 2013, and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor&nbsp;&amp; Media Contact: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Derek Cole </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">720.940.2163 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>derek.cole@arcabiopharma.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g739104arca.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g739104arca.jpg
M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``@&!@<&!0@'!P<*"0@*#18.#0P,#1L3%!`6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`%H`_P,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/?Z`"@".6XAMQF:9(QZNP'\ZB=2$/B:0U%O9$']IZ?_`,_U
MO_W]7_&LOK5#^=?>B_9S[,7^T]/_`.?ZW_[^K_C1]:H?SK[T'LY]F)_:>G_\
M_P!;_P#?U?\`&CZU0_G7WH/9S[,DBO;6=ML-S#(WHK@FKC6I3=HR3^9+A);H
MGK4D*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`
M*`,C7M8_LNW5(AFXE!V9Z+[UYV/QGU:%H_$]CHH4O:.[V.&=Y;F4R2NSN>K,
M<FOE)SE-\TG=GII**LB>&T,BM@<@9_"G&FY(3E8G2R)AD;'W<5I&BW%LESLR
M)K,B,OCC.!]:ATFE<?-K8JM&R'([=_2L]BSJ?#.M2S2?8;ERYQF-SUX[&OH<
MMQLIOV-1W[?Y'!B**2YXG45[IQ!0`4`<AX]\72>%K&U^RJCW4\O"N,C8/O?T
M'XTF[#2N=19W45]907<#;HID#J?8C-`B>F!%<F=;64VJQM<!3Y8D)"ENV2.U
M(#@M;\:>*?#2)+J>@6I@=MJRPW!*Y].G%*[15D0Z+X_\1^))98])\/6[^5C>
M\EP0JYZ<XHN%DC2O?$/C/2;=KJ\\.6L]N@R_V:Y)91ZX(HU%9%[POX[TKQ.W
MD0[K:\`SY$N,D>JGO33!JQU%,0V21(8VDE=4C099F.`!ZDT`<+>_$F*XU#^S
MO#>G2ZM='HP^6,>^?3WX%3<JQ>CB\>W2"22ZTBQ)_P"60B>0CZG-/46AGZIJ
M?C_086N'M=.U*W099H$8,H]=N<_EFEJAZ%[P+XSF\6)>BXM8K>2W*8$;$A@<
M^OTIIW$U8["F(*`.7\=>)G\,:$)[;8;R9PD*N,CU)(^G\Q2;L-*YM:/J4>KZ
M/::A%]RXC#X]#W'X'(H%L7J8!0`4`%`'%^+LG5H1_P!,1_Z$:^9S?^.O3]6>
MCA/@?J9UM"R,"5X]".#7F4XM.[.B3-^SL0&CN(!OC!PR=U]1[BO7HT-54AJN
MJ['+.>\66_L=O&ES"LT9+$;?F]#WKH]A3BIP4EKL9\\G9V([K3=P2-"%AB7+
M2'ID]3[U%;"WM%?"EN.-2VKW,"[B4MMB4[1T]3[FO(JQ3=HK0ZHON1:0ICUV
MT'0^8*>"NL3#U'5UIL]#K[,\@*`"@#Q3QA!<>*!K'B.)B;+3IEM80.C*/OM^
M9!_&H>I:TT.M^%&L_;?#DFG2-F6Q?"_[C<C]<BFA,[ZJ)"@#B/BM_P`B4_\`
MU\1_S-2QHR/@U_R#]6_ZZI_Z":$.1Z=C(P:HD^<[HMH_CR;["=IM[\B(+_O]
M/Z5!?0^C*L@\7^)'BJXU;5FT&P9OLL+A)`A_UTGI]`>,>M2V6E8]'\'^%[?P
MQH\<*JIO)`&N)>[-Z?04TK$MW.AIB"@#F-+\--H_C2_U"SC1-/O8`74'&V4-
MV'H1DTAWT.GIB"@#R'QK!<>++W6KRV<FTT*,1H!T=\YD_(#]!4O4I:&G\(=9
M\[3KO1Y&^>W;S8A_LMU_(_SH0,]+JB0H`*`"@#CO%2EM8BQ_SQ'_`*$U?,9N
MKUUZ?JST<+I!^HFFPW*X\L`CN"00?P-9X:%5?#^A51QZFAJDS6=K$BQ+!).2
M&*'L*[<5-T::27*Y;V[&-)*<F[WL/TT1;1NQ2PRAU%4OT+V8VE\@+O1AD+G'
M(KL3BY>SW3Z&6J5S*U&&ZVE1$D:?W4('Y^M<&)A5VLDO*QT4W'N8^G1E-<M,
MC'[P=Z\_"1:Q,/4WJ.]-G?5]D>2%`'-^.=:;1/#%P\)_TNX_<0`=2S<9'T&3
M2>@T2Z-X;@LO!D6AS*"'@*3>[,/F/YFBV@7U/)O!5[+X6\>BSNCL5Y&M)L],
MYX/Y@?G4K1E/5'O%60%`'$?%;_D27_Z^(_YU+&CE/AAXCTC0[+48]3OH[5I9
M%*;\\@`T+0;1V&H_$C1(H_*TJ1M3OY/EAAA0_,QZ9)IW%8PO!_P]O!JPUWQ#
MM$_F&9+?.3O)SN;\>U)(;9Z/?3FUT^YN!UBB9Q^`S3)/`/`\/]H>.M,\X[B9
MC*V>Y`+?S%2MRWL?0]60%`!0`4`%`&-XKUI?#_AN\O\`(\Q5VQ#U<\#_`!_"
MD]!HI^#="&F>$(+2Z3=-=*9;G=U9GZ@_A@4('N>3:3*_@GXBB*4E8H9S!(3W
MC;H?R(/X5.S*W1[]5D!0`4`%`'&^*SC6(?\`KB/_`$)J^8S?^.O3]6>CA?@?
MJ067E#!EDP/11DURT5#[;-)WZ&O<VJ:EIN(%\GRFS&SM]X]Q7ISI1Q-&T%RV
MV;>[.>,G3GKK<S8UU"W?RWM)@WLI/ZUP1AB*;Y7!FS<):IFO9PS1))<7"`N%
M_P!5GD`]2:]*A3G!.<UKVZV.><D[1C]YF7K6TF3$Q0_W7Y'YUY]=TI:PT]?\
MS>',MS/TW_D.68_Z:"N?!_[S#U-*O\-GH%?9GDA0!YOK$(\:?$1-)$TJ6&DQ
MEY7B;:PD..A['.!^!J=V5LC?_P"$'M_^@YKG_@<W^%.PKGF7Q$\-?\([J]O<
M03W$T5RN[S9WWOYBGG+?3%2U8I,]>\+:P-=\-65_G,CIMD]G'#?J*I$O0V*8
MCB/BM_R)+_\`7Q'_`#J6-&+\'X(I],U998DD7S4&&4'^$T(;,+XB^$O^$>U&
M/5=-0Q64[]$X\F3KQZ`]12:L-,]$\">*U\3:,!,P&H6P"SK_`'O1Q['^=4F2
MU8Z6YA%S:S0-]V1"A_$8H$?//AR8^'O'%G]J_=_9KDQ2Y[#E3_.I6A9]%U9`
M4`%`#7D2,#>ZKDX&3C)]*`'4`>=>*U_X2OQOI_AA)'%I:J;B[9#@@XX&?7&/
M^^JE[V*6B-S_`(0:W_Z#FM_^!S?X4["N>=_$GPHNARVE]#<75S'<9CD>YD\Q
M@PZ<_3^52U8I,])\":S_`&WX2LYG;,\(\F7_`'EXS^(P?QJD2]#I*8@H`*`.
M-\81LNHP28^5HMH/N"?\17S6<1:JQETM^IZ.$?N-&/;2A6&X\#L.]>3!J+U.
MF2[&U:W_`)D\9D.(HAG:.@`[5Z-*OS33ELCGE"RTW+BZFTEO=,S?,VTCGIS7
M2L4Y0FV][&;I)-%>ZU%G6*X1RLJ_*Q'KV-8U<2Y*-1/5:%QIVO'H9%W<B4EP
M`K'J!T^HKSZM13=T;QC;070T:;7+7:,[6W'Z`5K@(N6(A8FN[4V>A5]D>28_
MB77[;PYHL][.Z^8%(AC)YD?L!2V&D<U\*K9#H%UJ;R"2[O;AFE;.2,=`?S)_
M&DAL[VJ)..^)NG17O@RXF<JLEHRRH3]<$?B#2>PT<?\`"KQ-!I\]QH][,L4<
M["2!G.!OZ%?QX_*DAM'L-42<'\6;F&/PB+=I%$TLZ;$SR0,DG%2RD9'P;N85
M@U2V,BB9G1PA/)&",BA!(]'U73+;6-,N-/NTW0S+M/J/0CW!YID['@L,NI?#
M_P`8$$$R6[;6'031'_$?D:G8O<]XTG6+'6[&.\L+A98W&2`>5/H1V-41L>??
M$CP+->S/KFE1&24C_28%'+8_B4=SZBDT4F7/`/CRWO[2+2-5F$-_"-B/(<"4
M#IS_`'O;O0F#1Z'5$D5Q<P6<#SW$R0Q(,L[M@#\:0'FP\2)XS^(>F65EDZ78
M.T^XC'FNHX;'IG&*6[*M9'?:SK%IH6ES7]Y($CC7(7/+GLH]S3V)1Q7PL47X
MUC7KAU>]NKC:PSR@Z_ES^E)%,]%JB3F_'NG1:CX,U!)"JF%/.1B<89>?UY'X
MTGL-;GFOPO\`$L&CZK-87LPBMKP#:['"K(.F?3(X_*I131[:""`0<@]"*L@6
M@`H`J:AI\.I6K03#']UAU4^HKGQ&'AB(<DC2G4=-W1QEUX=U*UD(2$S)V:/G
M/X5\S6R[$4W9*Z\CT8XBG);V(DL-352/L,_/^P:P6%Q"V@_N*]I3[HD6TU((
MR_8I^<?P&J6'Q*37(_N%ST^XPV6IX(^PSX/^P:7U;$_R/[A^TI]Q(]%U2=PH
MLY%]W&T#\Z<,#B).R@_F#K4UU.LT31$TJ,N[![AQAF'0#T%?18+!+#*[UDS@
MK5G4T6QKUZ)SG*2_#KP[<S&:ZAN+F0Y^::Y=B/UI6'<=;?#[0+&Y2>SCN;9U
M8-B*Y<`X]1GFBP7.IIB.9U#P)HFJ7<EQ>BZF:1RY5KE]H/L,X%*P[E=OAEX4
M9<?V<P]Q,_\`C19!=FGIWA;3]+L;JSM9+L0W"[6#7#L5&"/E)/R]>U%@N9A^
M&OAIY-\]M/._]Z6Y=C^>:+(+L#\,_"X8-'92Q,.C)<."/UHL@NSH],TZ'2K%
M+.!Y7C3.#+(7;D^IYH$9VN^$M'\1S0S:E;%Y(055E<J<>AQUHL-.QG+\-_#<
M3;[>WN+=_P"]#<R*?YT6079U:((XU0$D*`!DY-,1A:SX+T#77,E[8)YYZS1'
M8_XD=?QI6'>QGQ>!9+-!%8^)M8MX1T3S@P'TR*+!<27X=:;>LK:IJ&IZB1VG
MN3M_(8HL%S7TGPKHFA3F?3=/C@F*["X)+$>F2?:BU@N4+OP!H%_=O<WL5Q<R
M.Q;]Y<N0,^@SQ18+D<?PY\.V\OF6L-S;/ZPW4BY_6BP7.K`P`*8CGM4\$Z/K
M-Y)<WWVJ4R$$I]I<(,#LN<"E8=[%,_#/PH5Q_9S#W\Y_\:+(+LV-$\/6/A^.
M6.Q:?RY,?)+,SA<9^Z#TZT)6"YK4Q!0`4`%`!0`4`%`!0`4`%`&?K.H2:98-
M<QHCD$##-CK_`#I/0:5RQ8M.]E$USCSF7+`#`&>U`,G)(4D#)`Z4Q%33;FZN
MK8O=6IMI`Q`4G.1ZTD-Z%RF(*`&LZH0&8#)P,GK2`=3`S]8OY--T]KF-$<J0
M,.V.O\Z3T&E<L6+SR6,+W./.9=S`#`&>U`,L4Q!0`4`%`!0`4`%`!0`4`%`!
M0`4`%`!0`4`%`!0`4`%`!0`4`%`'-:W.;O6[2PCC,HB/FL@_B/8'T'^-2REH
MBYIU[?MK5S979B81QAP8Q@+GM36XFE8?KFHSV%HS0*H;@!W&023P`.YH;L"1
M?MFE%E$]T0)=@,F.`#CF@1E)J=U?075W;,L%I`&V,RY,A`_04KE6L:6FW?V[
M3H+DKM,BY(]#30GH84_VG5_$2QH1`+)=P)`?#'IQZ_X4MV/9&CH6HSWT=PER
M%,L$FPLHP&IIB:L4?$DXEOK"PVLX+^8Z+U;T'\Z3&B9K_4K;6[.VG,)CN`?W
M:+]S\>]&MPLK&S<7$5K`TTS;47_.*9)CZIJ6H0P0^2D<4MPX2.-AN<>Y[?A[
MTFRDD:[-+%:@A3-*`!QQN/\`2F28%CJNJW\MY!`869&PLFTA5'/YY[4KLII(
MV[=[J/3U:[0/<A?F6+N?:F(QK;5]0N-6NK9!"RQKU`.V,]R3W[CWI7'96(K/
M6]0GLKR0O%M@)(G*87'H!W)HN%D;.CW%S=:7#/=@"5QG@8R.U-">@^:\8W!M
M;5!).!ER3\L8]_?VH"Q2TJ]O+[4+HO(AM83Y:[%P&;UI(;5C9JB0H`*`"@`H
M`*`"@`H`*`"@`H`*`.8TJ2>&ZOY7LIGOY9"!E<*%[?-TQ4HIFUIUA]C21Y'\
MRYF;?*_J?0>PIK039EWXN;SQ%%$+9VAMEW)D80N>Y/H/Z4NHUHC7OX99],N(
M8R/->,J,<9.*8D8:I/-HEOI-I"Z2,H6=W4J(QW^I^E+I8?6YN*L.EZ9@<16\
M?\A3V%N8.BW$D-A<3B"22^NG+JNPX(['/3'6DALV-'T[^S+$1NVZ9SOD;U8T
MTK";N9L9DAU"^U>XM)G*L(H45?FV]"<4O,?D7[:V:YU,ZE,C(`FR%&&"!W)]
M":8MM"KJDDXUVR4VLL]O&I<!!D%^@SVXI/<:V*MNE_<^))9Y[<[X1MBR#Y:9
MZG/?C/UHZAHD;>J2S0Z9.UO&SS;=J*HR<GBFQ(CT73QINFQPD?O#\TA]6-"5
M@;N2:I/-;:?*]O$\DV-J*HR<GO0P1C/I]QI^AI96L3/=7;`2R`9VYZY/Z4K6
M0[ZB:E9-`EAI%O;RO;9WRE!]_'8GM0^P+N;X,T=D247S50D(G3/8"F(YB*?4
M$\.S>3:3)<.Q::5E^9B3_".O3\JGH5U-K0K=[738XC%Y2``@-]XGN3Z52)9J
M4Q!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0!C:_'?W=H;2TM697(WOO4
M<>@R:3&K(U+90EM$@C,050`C8R,?3B@1+3`*`"@`H`*`"@`H`*`"@`H`*`"@
M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*
5`"@`H`*`"@`H`*`"@`H`*`"@#__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
